Get the Daily Brief
Latest Biotech News
Arthrosi closes $153M Series E to race to Phase 3 gout readouts
Arthrosi Therapeutics raised $153 million in a Series E financing led by Prime Eight Capital to complete two fully enrolled Phase 3 trials of AR882 (pozdeutinurad), a next‑generation URAT1...
Sanofi’s alpha radioligand hits Phase 2 goals – response in neuroendocrine tumors
Sanofi reported that AlphaMedix, its lead targeted alpha therapy developed with Orano Med and RadioMedix, met the primary endpoints in a Phase 2 study of unresectable or metastatic...
NIH backs longevity sequencing: $80M for family longevity study using PacBio HiFi
The Long Life Family Study (LLFS) received $80 million from the NIH to extend a large aging cohort and to generate long‑read genomic and epigenomic data using Pacific Biosciences’ Revio HiFi...
ARPA‑H funds teams to build in‑vivo cell therapies – government bets on delivery and mRNA
The Advanced Research Projects Agency for Health (ARPA‑H) awarded grants to seven teams to develop in‑vivo cell therapies that program immune cells inside the body using gene editing, mRNA and...
TransCode deal reshapes company: buys Polynoma, takes $25M and cedes control
TransCode Therapeutics struck a two‑part deal that acquires Polynoma and secures a $25 million investment from a CK Life Sciences subsidiary, a transaction that will leave CK owning about 91% of...
Soufflé rises with $200M: Langer‑backed RNA firm targets cell‑specific siRNA
Soufflé Therapeutics launched with a $200 million Series A to develop cell‑targeted RNA therapeutics, backed by founders and industry veterans including Moderna co‑founder Bob Langer. The company...
T-reg Nobel: immune tolerance wins Medicine prize
The 2025 Nobel Prize in Physiology or Medicine honored foundational work revealing regulatory T cells (T‑regs) as the immune system’s brake on autoimmunity. Stockholm’s Royal Swedish Academy and...
Sanofi’s AlphaMedix... phase 2 hits endpoints
Sanofi and radioligand partner Orano Med reported Phase 2 results for AlphaMedix (lead-212 payload) in gastroenteropancreatic neuroendocrine tumors (GEP‑NETs), meeting primary endpoints for...
FDA label change: Xeloda now recommends DPYD testing
The FDA updated Genentech’s Xeloda (capecitabine) label to explicitly recommend pre‑treatment testing for DPYD variants that confer dihydropyrimidine dehydrogenase (DPD) deficiency, elevating...
Neuro‑immunology startup raises $101M – Nilo launches
Nilo Therapeutics launched with $101 million in Series A funding to translate neuro‑immunology discoveries into drugs that target neural circuits to control systemic inflammation. The company was...
Lexeo positions Friedreich’s gene therapy for accelerated path
Lexeo Therapeutics said FDA discussions left the agency open to an accelerated approval pathway for LX‑2006, its Friedreich’s ataxia cardiomyopathy gene therapy, if pooled interim data from...
Scale-up push: Asimov stable AAV lines and Mytos automated CDMO
Asimov unveiled its AAV Edge Stable Producer system delivering clonal, HEK293-based, suspension producer cell lines to replace transient plasmid production and claim titers up to 6E15 vg/L...
Radiotheranostics momentum: UCLA radiotheranostic antibody and Full‑Life cash
UCLA-led researchers unveiled DUNP19, a radiotheranostic antibody targeting LRRC15 that detects, kills and reprograms aggressive, therapy‑resistant tumors including glioblastoma and osteosarcoma...
New IPF pill clears FDA: Boehringer’s Jascayd approved
The FDA approved Boehringer Ingelheim’s oral PDE4B inhibitor nerandomilast (Jascayd) for idiopathic pulmonary fibrosis (IPF), the first new drug approval for IPF in over a decade. Phase 3 evidence...
Epigenetics meets liquid biopsy: Tagomics paper and TruDiagnostic grant
Tagomics published a Cell Reports Methods paper describing Active‑Seq, an enzymatic, azide‑click tagging method that enriches unmethylated DNA for base‑conversion‑free epigenomic profiling in...
Diagnostics push: Owlstone lands ARPA‑H cash; Countable unveils 10‑color PCR
Owlstone Medical won up to $49.1 million from ARPA‑H to develop an at‑home, over‑the‑counter multi‑cancer breath test capable of detecting 30+ cancers at early stages — a program aimed at rapid,...
Sanofi’s alpha radioligand meets primary endpoints – Phase 2 success in GEP‑NETs
Sanofi and Orano Med reported that their lead alpha-emitting radiopharmaceutical candidate, AlphaMedix (also described in Sanofi’s AlphaMedix-02 study), met primary endpoints for overall response...
Nilo launches with $101M – neuro-immune startup targets brain‑body circuits
Nilo Therapeutics emerged from stealth with a $101 million Series A to develop therapeutics that modulate neural circuits governing systemic immune homeostasis. Founded by labs at Columbia, Yale...
Arthrosi nets $153M – bankroll to finish two Phase 3 gout trials
Arthrosi Therapeutics closed a $153 million Series E financing to fund completion of two Phase 3 trials for its gout candidate. The financing gives the San Diego biotech runway to deliver pivotal...
ARPA‑H backs at‑home multi‑cancer test – Owlstone lands up to $49.1M
Owlstone Medical secured up to $49.1 million from ARPA‑H to develop an over‑the‑counter, at‑home multi‑cancer screening test able to detect more than 30 cancers at early stages. The award funds...